000			nab a22 7a 4500
999			_c17574 _d17574
003			PC17574
005			20230718125123.0
008			230718b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aspa, eng
100			_93198 _aManzano, Miguel _eInstituto de Investigación imas12
100			_93313 _aMartínez, Ángel _eInstituto de Investigación imas12
100			_92644 _aVallet Regí, María _eInstituto de Investigación imas12
245	0	0	_aAuranofin-loaded nanoparticles as a new therapeutic tool to fight streptococcal infections. _h[artículo]
260			_bScientific reports, _c2016
300			_a6:19525.
500			_aFormato Vancouver: Díez Martínez R, García Fernández E, Manzano M, Martínez Á, Domenech M, Vallet Regí M et al. Auranofin-loaded nanoparticles as a new therapeutic tool to fight streptococcal infections. Sci Rep. 2016 Jan 18;6:19525.
501			_aPMID: 26776881 PMC4726118
504			_aContiene 53 referencias
520			_aDrug-loaded nanoparticles (NPs) can improve infection treatment by ensuring drug concentration at the right place within the therapeutic window. Poly(lactic-co-glycolic acid) (PLGA) NPs are able to enhance drug localization in target site and to sustainably release the entrapped molecule, reducing the secondary effects caused by systemic antibiotic administration. We have loaded auranofin, a gold compound traditionally used for treatment of rheumatoid arthritis, into PLGA NPs and their efficiency as antibacterial agent against two Gram-positive pathogens, Streptococcus pneumoniae and Streptococcus pyogenes was evaluated. Auranofin-PLGA NPs showed a strong bactericidal effect as cultures of multiresistant pneumococcal strains were practically sterilized after 6 h of treatment with such auranofin-NPs at 0.25 μM. Moreover, this potent bactericidal effect was also observed in S. pneumoniae and S. pyogenes biofilms, where the same concentration of auranofin-NPs was capable of decreasing the bacterial population about 4 logs more than free auranofin. These results were validated using a zebrafish embryo model demonstrating that treatment with auranofin loaded into NPs achieved a noticeable survival against pneumococcal infections. All these approaches displayed a clear superiority of loaded auranofin PLGA nanocarriers compared to free administration of the drug, which supports their potential application for the treatment of streptococcal infections.
710			_9625 _aInstituto de Investigación imas12
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726118/pdf/srep19525.pdf _yAcceso libre
942			_2ddc _cART _n0